SYSTEMIC THERAPY FOR ADVANCED OVARIAN CANCER IN BRCA1 MUTATION CARRIERS -NEW THERAPEUTIC APPROACHES: RESULTS OF A PROSPECTIVE NON-RANDOMIZED MULTI-CENTER STUDY


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. BRCA1-associated tumors demonstrate a unique sensitivity to platinum-based drugs, but the overall effectiveness of treatment remains limited. Despite the pronounced regression of the tumor, standard therapy with platinum-based drugs rarely leads to complete pathomorphological response. Objective: to evaluate the clinical efficacy, safety, frequency of complete pathomorphological responses of the new scheme of neoadjuvant therapy for patients with BRCA1-associated ovarian cancer (OC) using combination of mitomycin C and cisplatin. Methods. The study included 217 patients with OC who were treated during 2015-2017. Three oncological centers participated in the study. All patients with OC were subjected to polymerase chain reaction testing for mutations: BRCA1 c.5266dupC [5382insC], c.4034delA [4153delA], c.181T>G [C61G], c.68_69delAG [185delAG] prior to initiation of treatment. Of the 217 patients, 21 (10%) mutation carriers were identified; 12 (57%) patients received a combination of mitomycin C 10 mg/m2 and cisplatin 100 mg/m2 every 4 weeks in the neoadjuvant regimen. The results of a prospective study of the NACT of BRCAI-associated OC using combination of mitomycin C and cisplatin were compared to the retrospective data (n=62) of NACT of BRCA1-associated OC treated with standard neoadjuvant therapy. Results. All 12 OC patients demonstrated an objective clinical response to treatment. Complete cytoreductive surgery was achieved in all patients included in the study. The pathological evaluation of tissues removed during surgery established a complete pathomorphological response (pCR) in 2 (17%) of 12 cases. In addition, one patient had a complete pathomorphological r esponse in the ovaries and an almost complete response in the omentum. In general, 5 (42%) patients had a pronounced pathomorphological response (score 3, according to [12]). Conclusion. The combination of platinum doublets in combination with other drugs, whose activity is not limited to cells with BRCA1 deficiency, can be a promising chemotherapeutic approach. The use of platinum-taxane regimens, which are the current «gold» standard, apparently does not exceed other regimens in effectiveness for BRCA1 gene mutations carriers.

Толық мәтін

Рұқсат жабық

Авторлар туралы

T. Gorodnova

N.N. Petrov National Medical Research Center of Oncology

Email: t.gorodnova@mail.ru
PhD, oncologisT., researcher of the Department of oncogynecology St. Petersburg, Russia

A. Sokolenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Ivantsov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Kh. Kotiv

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

M. Yakovleva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

O. Mikheeva

Leningrad Regional Oncological Center

St. Petersburg, Russia

G. Mikhaylyuk

Leningrad Regional Oncological Center

St. Petersburg, Russia

A. Lisyanskaya

St. Petersburg State Healthcare Institution “City Clinical Oncology Center"; Pavlov First St. Petersburg State Medical University

St. Petersburg, Russia

K. Guseinov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. Nekrasova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

O. Smirnova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Sidoruk

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

N. Bondarev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

N. Matveeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. Meshkova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

N. Mikaya

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. Petrik

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

G. Manikhas

St. Petersburg State Healthcare Institution “City Clinical Oncology Center"; Pavlov First St. Petersburg State Medical University

St. Petersburg, Russia

S. Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. Berlev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Belyaev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. Imyanitov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Әдебиет тізімі

  1. du Bos A., Reuss A., Pujade-Lauraine E., et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-Doi: https://doi.org/10.1002/cncr.24149.
  2. du Bois A., Kristensen G., Ray-Coquard I., et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. Oncol. 2016;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6.
  3. Берлев И.В., Карачун А.М., Городнова Т.В., и др. Циторедуктивные операции с перитонэктомией у больных раком яичников: технические аспекты и непосредственные результаты. Вопросы онкологии. 2018;65(3.):в печати. [Berlev I.V., Karachun A.M., Gorodnova T.V, et al. Cytoreductive surgery with peritonectomy in patients with ovarian cancer: technical aspects and immediate results. Voprosy onkologii. 2018;65(3.):in press. (In Russ.)].
  4. Vergote I., Tropé C.G., Amant F, et al.; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 201;363(10):943-53. Doi: 10.1056/ NEJMoa0908806.
  5. Leary A., Cowan R., Chi D., et al. Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues. Am. Soc. Clin. Oncol. Educ. Book. 2016;35:153-62. Doi: 10.1056/ NEJMoa0908806.
  6. Lord C.J., Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 2013;19(11):1381-88. doi: 10.1038/nm.3369.
  7. Sokolenko A.Р., Savonevich E.L., Ivantsov A.O., et al. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. Cancer Lett. 2017;397:127-32. Doi: https://doi.org/10.1016/j. canlet.2017.03.036
  8. Kehoe S., Hook J., Nankivell M., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6.
  9. Martins F.C., De S., Almendro V., et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012;2(6):503-11.
  10. Suidan R.S., Ramirez P.T., Sarasohn D.M., et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol. Oncol. 2014;134(3):455-61. Doi: https://doi. org/10.1016/j.ygyno.2014.07.002
  11. Соколенко А.П., Иевлева А.Г., Митюшкина Н.В., и др. Синдром наследственного рака молочной железы и яичников в Российской Федерации. Acta naturae. 2010;4:35-9.
  12. Bohm S., Faruqi A., Said I., et al. Chemotherapy response score: developmentand validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J. Clin. Oncol. 2015;33:2457-63. doi: 10.1200/Jœ.2014.60.5212.
  13. Maxwell K.N., Wubbenhorst B., Wenz B.M., et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat. Commun. 2017;8(1):319. doi: 10.1038/s41467-017-00388-9.
  14. Petrillo M., Zannoni G.F., Tortorella L., et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am. J. Obstet. Gynecol. 2014;211(6):632.e1-8.
  15. Bonnefoi H., Litière S., Piccart M., et al.; EORTC 10994/BIG 1-00 Study investigators. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann. Oncol. 2014;25(6):1128-36. doi: 10.1093/annonc/ mdu118.
  16. Cortazar Р., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8.
  17. Gorodnova T.V., Sokolenko A.Р., Ivantsov A.O., et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation, Cancer Lett. 2015;369:363-67. Doi: 10.1016f.caniet.2015.08.028.
  18. Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 2010;28(3):375-79. doi: 10.1200/Jœ.2008. 20.7019.
  19. Pfeifer W., Sokolenko A.Р., Potapova O.N., et al. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. Breast Cancer Res. Treat. 2014;148(3):675-83. doi: 10.1007/s10549-014-3206-1
  20. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 2014;124(1):1-5. Doi: 10.1016/j. ijgo.2013.10.001.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2018

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>